logo
logo

Micreos Secures €32 Million For Its Endolysin-Based Platform As Sustainable Alternative To Antibiotics

Sep 30, 2021•almost 4 years ago

Amount Raised

€32 Million

The Hague

Description

Dutch biotechnology company Micreos announced it has secured another €32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria. This funding round will help Micreos accelerate its clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstream infections, based on its pharmaceutical lead compounds, XZ.700 and SP.800.

Company Information

Company

Micreos.

Location

The Hague, South Holland, Netherlands

About

Micreos develops new biological therapies based on targeted killing of only unwanted bacteria, set to replace antibiotics in a wide range of applications, The company is viewed as a global leader in this field. Its proprietary endolysin technology has been created together with the Swiss Federal Technology Institute, ETH Zurich. Headquartered in The Hague, The Netherlands, Micreos runs its technology center in Zurich, with operations in the Netherlands and the USA. Under the Gladskin brand, Micreos has launched several endolysin-based OTC products for people with inflammatory skin conditions caused or aggravated by S. aureus, including acne, eczema and rosacea, and helped hundreds of thousands of people. SOURCE Micreos

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech